Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.

  title={Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.},
  author={Peter Valent and Emir Hadzijusufovic and G H Schernthaner and Dominik Georg Friedrich Wolf and Delphine Rea and Philipp le Coutre},
  volume={125 6},
Vascular safety is an emerging issue in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs). Whereas imatinib exhibits a well-documented and favorable long-term safety profile without obvious accumulation of vascular events, several types of vascular adverse events (VAEs) have been described in patients receiving second- or third-generation BCR/ABL1 TKIs. Such VAEs include pulmonary hypertension in patients treated with dasatinib, peripheral arterial… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 70 extracted citations


Publications referenced by this paper.
Showing 1-10 of 65 references

Efficacy and safety of ponatinib following failure of dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) in the PACE trial

A Hochhaus, JE Cortes, DW Kim
View 5 Excerpts
Highly Influenced

Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potential explanation for drug-iduced vasculopathy

E Hadzijusufovic, K Albrecht-Schgoer, K Huber
in CML. Blood • 2013
View 9 Excerpts
Highly Influenced

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2012
View 6 Excerpts
Highly Influenced

Ponatinib in refractory Philadelphia chromosome-positive leukemias.

The New England journal of medicine • 2012
View 10 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…